Sandoz B.V. v. Bristol-Myers Squibb Holdings Ireland Unlimited Company and Teva B.V., Teva Nederland B.V. & Pharmachemie B.V. v. Bristol-Myers Squibb Holdings Ireland Unlimited Company, Supreme Court of The Netherlands, Case nos. ECLI:NL:HR:2025:260 and ECLI:NL:HR:2025:262
Apixaban – Inventive step – Interpretation G 2/21 – Validity Transfer Priority Rights
The Supreme Court dismissed the appeal in cassation lodged by the generics without further motivation. A-G Van Peursem concluded earlier that the appeal in cassation should be dismissed.
An earlier post about the opinion of the A-G can be read here.
